Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	7 Months Ended	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2011	May 31, 2010	May 31, 2009	Dec. 31, 2011 Eclipsys [Member]	May 31, 2010 Eclipsys [Member]	May 31, 2009 Eclipsys [Member]	Dec. 31, 2011 Allscripts [Member]	May 31, 2010 Allscripts [Member]	May 31, 2009 Allscripts [Member]
Cash flows from operating activities:
Net income (loss)	$ (5,565)	$ 73,609	$ 62,870	$ 26,022
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	50,089	132,400	36,522	22,787
Stock-based compensation expense	18,916	40,752	14,849	5,770
Excess tax benefits from stock-based compensation	457	(8,818)	(6,251)	(5,463)
Provision for doubtful accounts	6,140	10,059	7,785	5,893
Deferred taxes	(3,825)	33,395	31,562	(1,194)
Other losses (gains)	476	3,513	(460)	0
Asset impairment losses	0	0	0	15,876
Loss on sale of prepackaged medications business	0	0	0	1,588
Changes in operating assets and liabilities, net of business combinations:
Accounts receivable	(5,237)	(55,912)	(34,583)	(30,303)
Inventories	321	1,757	(601)	231
Prepaid expenses and other assets	(11,843)	(33,025)	(18,094)	(6,858)
Accounts payable	(10,413)	(8,546)	13,056	(2,924)
Accrued expenses	10,377	22,298	14,775	(2,036)
Accrued compensation and benefits	448	(14,766)	709	(7,740)
Deferred revenue	25,288	72,728	18,092	14,577
Other liabilities	152	(690)	(313)	(149)
Net cash provided by operating activities	75,781	268,754	139,918	36,077
Cash flows from investing activities:
Capital expenditures	(24,552)	(44,306)	(13,919)	(4,970)
Capitalized software	(36,936)	(60,748)	(21,097)	(14,001)
Purchases of marketable securities and other investments	(9)	(12,900)	(4,008)	(2,522)
Sales and maturities of marketable securities and other investments	1,598	55	7,017	8,703
Proceeds received from sale of fixed assets	0	20,000	0	0
Change in restricted cash	2,216	2,225	0	0
Net cash acquired in merger					0	0	0	0	0	65,728
Payment for acquisition of Allscripts	0	0	0	(329,494)
Net proceeds received from sale of building	0	0	0	6,450
Net proceeds received from sale of prepackaged medications business	0	0	0	8,000
Net cash (used in) provided by investing activities	112,419	(95,674)	(32,007)	(262,106)
Cash flows from financing activities:
Proceeds from issuance of common stock	10,426	35,119	3,594	5,620
Excess tax benefits from stock-based compensation	(457)	8,818	6,251	5,463
Taxes paid related to net share settlement of equity awards	0	(11,456)	0	0
Payments of capital lease obligations	(830)	(1,427)	(1,510)	(1,340)
Credit facility payments	(80,875)	(170,424)	(43,995)	(6,005)
Credit facility borrowings, net of issuance costs	547,744	47,193	0	0
Payments on promissory note	0	0	0	(2,734)
Line of credit payments	0	0	0	(41,915)
Line of credit borrowings	0	0	0	38,683
Change in parent's net investment, including $330,000 received from Misys PLC	0	0	0	358,802
Repurchase of senior convertible notes	0	0	0	(8,164)
Repurchase of common stock	(679,000)	(51,462)	0	(51,547)
Net cash (used in) provided by financing activities	(202,992)	(143,639)	(35,660)	296,863
Effect of exchange rates on cash and cash equivalents	785	(1,091)	0	0
Net increase (decrease) in cash and cash equivalents	(14,007)	28,350	72,251	70,834
Cash and cash equivalents, beginning of period	143,410	129,403	71,159	325
Cash and cash equivalents, end of period	$ 129,403	$ 157,753	$ 143,410	$ 71,159